Please login to the form below

Not currently logged in
Email:
Password:

G-BA

This page shows the latest G-BA news and features for those working in and with pharma, biotech and healthcare.

UK, Germany back routine use of J&J’s Tremfya

UK, Germany back routine use of J&J’s Tremfya

The National Institute for Health and Care Excellence (NICE) for England and Wales, the Scottish Medicines Consortium (SMC) and Germany’s Federal Joint Committee (G-BA) are the first health technology ... Meanwhile the G-BA has published its decision

Latest news

More from news
Approximately 5 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • The price is right? The price is right?

    The company is obliged to submit an application for the assessment of potential additional benefit, providing the G-BA with a value dossier to be evaluated by IQWiG. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    PME that it currently has no other commissions from the G-BA to assess other biologic products.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). ... A key step is a positive assessment by the G-BA of a drug's added benefit relative to

  • Oncology drugs under AMNOG: part one Oncology drugs under AMNOG: part one

    Instead, they are reimbursed at the manufacturer's price only during the first year on the market, while the Federal Joint Committee (G-BA) assesses the new product or indication for ... The G-BA also rules on the strength of evidence of the added benefit

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    IQWiG's recommendation is not final, however, and once an evidence report is create, it is then passed to a public legal entity called the Federal Joint Committee (G-BA). ... There is a hearing at G-BA in which criticism can be discussed,” she says.

More from intelligence
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    The G-BA also rules on the strength of evidence of the added benefit. ... explore other options to better address the likely requirements of the G-BA.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics